



Congress of
Neurological
Surgeons

2021 Tumor Section Symposium

October 15-16, 2021

Austin, TX

RELEVANT CONFLICT OF INTEREST DISCLOSURES AND EDUCATIONAL GRANTS

ACCREDITATION

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Congress of Neurological Surgeons and the Tumor Section. The Congress of Neurological Surgeons is accredited by the ACCME to provide continuing medical education for physicians

AMA Credit Designation Statement(s)

The Congress of Neurological Surgeons designates this Live Activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

RELEVANT CONFLICT OF INTEREST DISCLOSURES

CNS Disclosure Policy

The Congress of Neurological Surgeons controls the content and production of this CME activity and attempts to assure the presentation of balanced, objective information. In accordance with the Standards for Integrity and Independence in Accredited Continuing Education established by the Accreditation Council for Continuing Medical Education (ACCME), speakers are asked to disclose all relationships they have with ineligible companies* over the previous 24 months which may be related to the content of their lecture. Speakers who have disclosed a relationship with an ineligible company whose products may have relevance to their presentation are listed below.

Any planner, reviewer, or faculty member not on the disclosure list has reported they have nothing to disclose.

All relevant financial relationships listed for these individuals have been mitigated.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. An ineligible company is not eligible for ACCME accreditation or participation in Joint Providership.*

List As of 10/12/2021



Reviewers

Individual's Name	Name(s) of Ineligible Company	Nature of Relationship(s)
Maryam Rahman		Nothing to Disclose
Garni Barkhoudarian	Vascular Technologies, Inc., CereVasc, Inc.	Consulting Fee

Planners

Individual's Name	Name(s) of Ineligible Company	Nature of Relationship(s)
Michael A. Vogelbaum	Infuseon Therapeutics	Royalty
		Receipt of IP
		Ownership Interest - Future Stock Options
Ian F. Dunn	Celgene, Tocagen, Cellinta, Plus Therapeutics	Consulting Fee

Faculty

Individual's Name	Name(s) of Ineligible Company	Nature of Relationship(s)
Garni Barkhoudarian	Consultant - Vascular Technologies Inc (VTI) Consultant - Cerevasc	Consulting Fee
Mark H. Bilsky	Globus Medical Acromed Depuy Spine	Royalty
Veronica Chiang	Monteris medical inc MRI Interventions	Consulting Fee
Christopher Paul Cifarelli	Carl Zeiss Meditec AG.	Speakers Bureau
Gavin P. Dunn	Ziopharm Oncology, ImmunoGenesis	Consulting Fee
	Immunovalent	Ownership Interest - Own Stock
Michael E. Ivan	Medtronic, Invenio	Consulting Fee
Daniel F. Kelly	Mizuho, Inc.	Royalty
Tyler J Kenning	Stryker CMF, Collagen Matrix	Consulting Fee
Frederick F. Lang	DNatrix, Inc	Receipt of IP
Michael Lim	Tocagen, BMS, VBI, InCephalo therapeutics, Pyramid Bio, Merck, Arbor, Novocure, Insightec, Biohaven, Sanianoia, Hemispherian, Black Diamond Therapeutics	Consulting Fee
	Tocagen, BMS, VBI, InCephalo therapeutics, Pyramid Bio, Merck, Arbor, Novocure, Insightec, Biohaven, Sanianoia, Hemispherian, Black Diamond Therapeutics	Receipt of IP



Russell R. Lonser	Spark Therapeutics, Voyager Therapeutics Merck	Consulting Fee
José del R. Millán	ATAI Life Sciences, Germany	Consulting Fee
Le Min	Cortcept : PI for phase 3 clinical trail of GR antagonist on Cushing syndrome	Contracted Research
Jennifer A. Moliterno	BK Ultrasound	Consulting Fee
Edjah K. Nduom	Bristol-Myers Squibb	Contracted Research
Daniel A. Orringer	Stryker Instruments, NX Development Corp	Consulting Fee
	Invenio Imaging Inc.	Ownership Interest - Future Stock Options
Ian F. Parney	AbbVie Pharmaceuticals	Consulting Fee
	Merck Pharmaceuticals	Contracted Research
Daniel M. Prevedello	Stryker, Integra	Consulting Fee
	Integra, Storz	Contracted Research
	Mizuho	Fees For Non CME Services
	KLS-Martin	Receipt of IP
	ACE Medical, Mizuho	Royalty
	Storz	Speakers Bureau
Pablo F. Recinos	Stryker	Consulting Fee
Andrew E. Sloan	Monteris Medical, Inc. Surgical Theatre, LLC	Consulting Fee
Andrew E. Sloan	Merck Pharmaceuticals Monteris Medical	Contracted Research
Michael A. Vogelbaum	Celgene, Tocagen, Cellinta, Plus Therapeutics	Consulting Fee
	Infuseon Therapeutics	Ownership Interest - Future Stock Options
		Receipt of IP
		Royalty
Isaac Yang	Baxter	Consulting Fee
Gabriel Zada	Stryker, Rebound Therapeutics	Consulting Fee
	Elekta, Nico	Speakers Bureau

Agenda and faculty subject to change

As of October 13, 2021

EDUCATION GRANTS & IN-KIND EQUIPMENT

Commercial Support:



Congress of Neurological Surgeons

Congress of Neurological Surgeons wishes to recognize and thank the following for providing an educational grant and/or use of equipment (in-kind):

Name of Commercial Supporter	In-Kind	Financial
Novocure, Inc.	N/A	Yes